<DOC>
	<DOC>NCT03090737</DOC>
	<brief_summary>A study to evaluate the safety of Nivolumab in patients with advanced or metastatic non-small cell lung cancer</brief_summary>
	<brief_title>Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Non small cell lung cancer (Squamous or nonsquamous) One prior anticancer therapy that did not work ECOG Performance Scale 01 Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug Active, known or suspected autoimmune disease or infection Prior immunooncology therapy Corticosteroids within 2 weeks of study drug administration Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>